Lecanemab drug trial to examine if it can slow progress of Alzheimer's disease
1 year, 4 months ago

Lecanemab drug trial to examine if it can slow progress of Alzheimer's disease

ABC  

When 69-year-old Margaret Williamson was told she was at high risk of developing dementia, she was shocked. A screening at the Hunter Medical Research Institute in 2022 detected that Margaret and her identical twin sister, Marilyn, had the amyloid protein in their brains, believed to be the leading cause of Alzheimer's disease. Professor Michael Breakspear is hoping the drug trial can determine if Lecanemab can prevent Alzheimer's disease. If you or anyone you know needs help: The National Dementia Helpline on 1800 100 500 Lifeline on 13 11 14 Beyond Blue on 1300 224 636 Suicide Call Back Service on 1300 659 467 Dementia Support Australia for carers of people living with dementia on 1800 699 799 Overseas studies have shown that Lecanamab can slow cognitive decline caused by Alzheimer's by 25 per cent. "What we're doing is targeting people who are yet to develop Alzheimer's but have low levels of amyloid," Professor Breakspear said.

Disease Trial Dementia Newcastle Margaret High Risk Cara Tga Breakspear Hunter Medical Research Institute Hmri Lecanemab Drug  research  medical  dementia  slow  alzheimers  trial  examine  disease  breakspear  margaret  lecanemab  drug  progress

History of this topic

Second 'wonder' drug for Alzheimer's hailed by scientists as the 'best ever' treatment for the disease set to be blocked for NHS use
6 months, 2 weeks ago

Second 'wonder' drug for Alzheimer's hailed by scientists as the 'best ever' treatment for the disease set to be blocked for NHS use

Daily Mail  

A second Alzheimer’s drug is expected to be blocked for use by the NHS, it has been reported. Donanemab – hailed by scientists as the ‘best ever’ treatment for the disease – has been shown in trials to slow cognitive decline by more than a third. Defending its ruling on lecanemab, Nice said the costs were ‘considerably above the range …

Second Alzheimer’s drug expected to be blocked for NHS use
6 months, 3 weeks ago

Second Alzheimer’s drug expected to be blocked for NHS use

The Telegraph  

A second Alzheimer’s drug is expected to be blocked for use by the NHS, The Telegraph can reveal. This week, the breakthrough drug lecanemab was declared safe by the medicines regulator but was not approved for use on the NHS by the health service’s spending watchdog. Insiders told The Telegraph that the National Institute for Health and Care Excellence, which …

Navigating new Alzheimer's drugs can be confusing and expensive. So do they really help patients?
1 year, 6 months ago

Navigating new Alzheimer's drugs can be confusing and expensive. So do they really help patients?

Salon  

For decades, attempts to treat or slow Alzheimer's disease — a brain disorder that causes dementia through damage to brain cells and other changes in the brain — have been dispiriting failures. "Our hope is that these are firsts for our field," Dr. Maria Carrillo, chief science officer of the Alzheimer's Association, told Salon in a video call about the …

New Alzheimer’s wonder drug ‘can slow disease progression by 60pc’
1 year, 7 months ago

New Alzheimer’s wonder drug ‘can slow disease progression by 60pc’

The Telegraph  

The NHS has just 88 positron emission tomography scanners which can detect amyloid plaques in the brain, one of the lowest per capita in the developed world. Hilary Evans, the chief executive of Alzheimer’s Research UK said: “Probably only two per cent of the people who could benefit from these drugs would necessarily get them because of those hurdles in …

New drug for Alzheimer's gives hope and ushers in new era in fighting the disease, says doctor
1 year, 8 months ago

New drug for Alzheimer's gives hope and ushers in new era in fighting the disease, says doctor

NL Times  

Alzheimer's used to be a disease that could not be cured. On Monday, however, the results of the second new drug for Alzheimer's will be announced, and that seems to herald a new era, says neurologist Niels Prins, director of the Brain Research Center. "It will be possible to counteract the disease, and that has never been done before in …

FDA panel unanimously endorses Lecanemab for Alzheimer's treatment, offering hope to millions
1 year, 9 months ago

FDA panel unanimously endorses Lecanemab for Alzheimer's treatment, offering hope to millions

Hindustan Times  

A major breakthrough in Alzheimer's treatment has emerged as the Food and Drug Administration panel unanimously endorsed the use of lecanemab to combat the progression of the debilitating disease. Clinical trial results of lecanemab were hailed as "robust" and "clear and consistent" by experts, offering a glimmer of hope for the estimated 6.5 million individuals affected by Alzheimer's. Researchers from …

Alzheimer's drug gets FDA panel's backing, setting the stage for broader use
1 year, 9 months ago

Alzheimer's drug gets FDA panel's backing, setting the stage for broader use

The Hindu  

Health advisers on Friday unanimously backed the full approval of a closely watched Alzheimer’s drug, a key step toward opening insurance coverage to U.S. seniors with early stages of the brain-robbing disease. The FDA panel of outside advisers voted 6-0 that a large company study confirmed the drug's benefits for patients with mild or early Alzheimer's. The FDA’s initial OK …

Alzheimer’s drug gets FDA panel’s backing, setting the stage for broader use
1 year, 9 months ago

Alzheimer’s drug gets FDA panel’s backing, setting the stage for broader use

Associated Press  

WASHINGTON — Health advisers on Friday unanimously backed the full approval of a closely watched Alzheimer’s drug, a key step toward opening insurance coverage to U.S. seniors with early stages of the brain-robbing disease. The FDA panel of outside advisers voted 6-0 that a large company study confirmed the drug’s benefits for patients with mild or early Alzheimer’s. The FDA’s …

First ever drug found to slow Alzheimer’s submitted for approval
1 year, 9 months ago

First ever drug found to slow Alzheimer’s submitted for approval

The Telegraph  

The first ever drug found to slow Alzheimer’s has gone to Britain’s regulators for approval. The findings of the phase-three clinical trial were the first to ever show a drug can slow Alzheimer’s. Richard Oakley, Associate Director of Research at Alzheimer’s Society, said: “This is exciting progress and means that we could hear if lecanemab has been approved by early …

Alzheimer’s drug lowers levels of protein known to cause disease, suggests study
1 year, 10 months ago

Alzheimer’s drug lowers levels of protein known to cause disease, suggests study

The Independent  

Sign up for our free Health Check email to receive exclusive analysis on the week in health Get our free Health Check email Get our free Health Check email SIGN UP I would like to be emailed about offers, events and updates from The Independent. The results are a significant step forward in demonstrating that we can successfully target tau …

Benefits of lecanemab, a new Alzheimer's drug, unclear for patients of color : Short Wave : NPR
2 years ago

Benefits of lecanemab, a new Alzheimer's drug, unclear for patients of color : Short Wave : NPR

NPR  

How well does a new Alzheimer's drug work for those most at risk? A new drug for Alzheimer's disease, called lecanemab, got a lot of attention earlier this year for getting fast-tracked approval based on a clinical trial that included nearly 1,800 people. The clinical trial for lecanemab was the most diverse for an Alzheimer's treatment to date, but it …

U.S. approves Alzheimer’s drug that modestly slows disease
2 years, 2 months ago

U.S. approves Alzheimer’s drug that modestly slows disease

LA Times  

This Dec. 21, 2022 image provided by Eisai in January 2023, shows vials and packaging for their medication Leqembi. U.S. health officials on Friday approved a closely watched Alzheimer’s drug that modestly slows the brain-robbing disease, albeit with potential safety risks that patients and their doctors will have to carefully weigh. Last week, a congressional report found that FDA’s approval …

Concerns about breakthrough Alzheimer's drug grow as THIRD patient in landmark trial dies from it
2 years, 2 months ago

Concerns about breakthrough Alzheimer's drug grow as THIRD patient in landmark trial dies from it

Daily Mail  

A third patient has died while being treated with an experimental Alzheimer's drug that doctors hope will herald the 'beginning of the end' for the condition. The patient was in the extension phase of the phase 3 trials for antibody drug lecanemab, backed by biotech company Eisai. It is the latest blow to trials of the drug which found it …

Alzheimer's drug breakthrough 阿尔茨海默病治疗药物获重大突破
2 years, 2 months ago

Alzheimer's drug breakthrough 阿尔茨海默病治疗药物获重大突破

China Daily  

媒体英语 Alzheimer's drug breakthrough 阿尔茨海默病治疗药物获重大突破 Play audio file 新试验发现首个减缓阿尔茨海默病对患者大脑损伤的药物，这个名为 “ lecanemab ” 的药物 “意义重大”。这项试验的结果为此领域几十年的高失败率画上句号，并表明用药物治疗阿尔茨海默病（最常见的失智症）的新时代并非遥不可及。 News of the first drug that can slow the progression of Alzheimer's has been called historic and prompted huge excitement among researchers and charities. It is only suitable for those with early-stage Alzheimer's, but few patients in the UK have the confirmatory diagnostic test needed to …

Explained | Will new drug slow progress of Alzheimer’s?
2 years, 3 months ago

Explained | Will new drug slow progress of Alzheimer’s?

The Hindu  

The story so far: In late November, news of the success of a drug to reduce cognitive decline in patients with Alzheimer’s disease burst on the horizon with all the promise of being a silver bullet. This class of drugs does precisely that.” As per the NEJM paper, the clinical trial, conducted over 18-months, a multi-centre, double-blind, phase 3 trial, …

Scientists hail breakthrough as drug proven to slow Alzheimer’s disease
2 years, 3 months ago

Scientists hail breakthrough as drug proven to slow Alzheimer’s disease

The Independent  

Scientists are hailing a historic step in the fight against Alzheimer’s, after a drug was proven to slow the disease in long-awaited clinical trials. Scientists also used blood tests and brain scans to search for levels of amyloid among the participants – discovering that they had fallen so significantly in those given lecanemab that some patients no longer technically met …

Is the new drug lecanemab a breakthrough for Alzheimer’s?
2 years, 3 months ago

Is the new drug lecanemab a breakthrough for Alzheimer’s?

Hindustan Times  

There’s news in the world of Alzheimer’s research. In a phase three trial, drug companies Biogen and Eisai reported this week that lecanemab, an experimental monoclonal antibody, reduced cognitive decline caused by the disease by 27% after 18 months. This trial proves that Alzheimer’s disease can be treated," Bart De Strooper, Director of the UK Dementia Research Institute, told reporters. …

Alzheimer's drug from Eisai and Biogen slows cognitive decline, side-effects in focus
2 years, 3 months ago

Alzheimer's drug from Eisai and Biogen slows cognitive decline, side-effects in focus

The Hindu  

An experimental Alzheimer's disease drug from Eisai and Biogen slowed cognitive decline in a closely watched trial but may carry a risk of dangerous side effects for certain patients, according to new data presented on Tuesday. The companies said in September that the 18-month trial, which enrolled nearly 1,800 participants with early-stage Alzheimer's, found that treatment with lecanemab reduced the …

Lecanemab: New Alzheimer´s drug hailed as 'beginning of the end'
2 years, 3 months ago

Lecanemab: New Alzheimer´s drug hailed as 'beginning of the end'

Daily Mail  

A game-changing new Alzheimer's drug may mark the 'beginning of the end' in the decades-long search for an effective treatment, leading experts claimed today. An experimental Alzheimer's drug, called lecanemab, has significantly slowed cognitive and functional decline by 27 per cent in a large patient trial. Pictured: brain scan of person with Alzheimer's The drug, created by Japanese pharmaceutical company …

New Alzheimer’s drug hailed as ‘beginning of the end’ in search for treatment
2 years, 3 months ago

New Alzheimer’s drug hailed as ‘beginning of the end’ in search for treatment

The Independent  

Get the free Morning Headlines email for news from our reporters across the world Sign up to our free Morning Headlines email Sign up to our free Morning Headlines email SIGN UP I would like to be emailed about offers, events and updates from The Independent. Read our privacy policy Experts have hailed the “beginning of the end” in the …

New drug appears to slow Alzheimer’s, but can it make a real difference?
2 years, 3 months ago

New drug appears to slow Alzheimer’s, but can it make a real difference?

LA Times  

An experimental Alzheimer’s drug modestly slowed the brain disease’s inevitable worsening, researchers reported Tuesday — but it remains unclear how much difference that might make in people’s lives. Japanese drugmaker Eisai and its U.S. partner, Biogen, had announced earlier this fall that the drug, lecanemab, appeared to work, a badly needed bright spot after repeated disappointments in the quest for …

Study: Alzheimer's drug shows modest success slowing declines in memory, thinking
2 years, 3 months ago

Study: Alzheimer's drug shows modest success slowing declines in memory, thinking

NPR  

Study: Alzheimer's drug shows modest success slowing declines in memory, thinking Enlarge this image toggle caption NATIONAL INSTITUTE ON AGING, NIH/AP NATIONAL INSTITUTE ON AGING, NIH/AP An experimental drug that removes a substance called amyloid from the brain appears to slow down Alzheimer's disease. The drug, called lecanemab, reduced the rate of cognitive decline by 27% in a study of …

Drug that reverses dementia will be wasted without better diagnosis rates, experts warn
2 years, 3 months ago

Drug that reverses dementia will be wasted without better diagnosis rates, experts warn

The Telegraph  

The latest published data shows that as of 2019, Britain had just 70 PET-CT scanning locations, less than half the number of those available in comparable EU countries. “We need everyone to be told which disease is causing their dementia symptoms, and if they have Alzheimer’s disease, a follow-up scan or CSF test to check if they are amyloid positive …

Alzheimer’s jab failed to meet goal on reducing memory decline, company says
2 years, 4 months ago

Alzheimer’s jab failed to meet goal on reducing memory decline, company says

The Independent  

Sign up for our free Health Check email to receive exclusive analysis on the week in health Get our free Health Check email Get our free Health Check email SIGN UP I would like to be emailed about offers, events and updates from The Independent. Read our privacy policy A new jab for people with early-stage Alzheimer’s has failed to …

Alzheimer’s drug shows promise in early results of study
2 years, 5 months ago

Alzheimer’s drug shows promise in early results of study

Associated Press  

Shares of Biogen and other drugmakers researching Alzheimer’s disease soared Wednesday after Japan’s Eisai Co. said its potential treatment appeared to slow the fatal disease in a late-stage study. The drugmaker said early results showed that its treatment, lecanemab, reduced patient clinical decline by 27% when compared to a placebo or fake drug after 18 months of the infused treatment. …

'Huge breakthrough' for Alzheimer's
2 years, 5 months ago

'Huge breakthrough' for Alzheimer's

Daily Mail  

An experimental Alzheimer's drug slows the mental deterioration of patients battling the earliest stages of the cruel disease by more than a quarter, promising trial results revealed today. An experimental Alzheimer's drug, called lecanemab, has significantly slowed cognitive and functional decline by 27 per cent in a large patient trial Dr Susan Kohlhaas, director of research at Alzheimer's Research UK, …

ANOTHER Alzheimer's drug fails: Trials of an experimental treatment cancelled two years early
6 years, 1 month ago

ANOTHER Alzheimer's drug fails: Trials of an experimental treatment cancelled two years early

Daily Mail  

Roche Holding will halt two late-stage clinical trials of its crenezumab drug for early Alzheimer's disease after an interim analysis indicated it was unlikely to hit its primary goal, the Swiss drugmaker said on Wednesday. Roche said an Alzheimer's Prevention Initiative study of crenezumab in familial Alzheimer's disease in Colombia would continue and that it remained committed to ongoing clinical …

Alzheimer's: Experimental drug offers hope to families with legacy of degenerative brain disease
9 years, 6 months ago

Alzheimer's: Experimental drug offers hope to families with legacy of degenerative brain disease

ABC  

When Amanda Ayliffe was just 34 years old she decided to find out whether she had a future or not. Alzheimer's trial The trial: 200 people globally with a family history of Alzheimer's The drug: Targets amyloids that build up and create plaques in the brain, it binds to them and is flushed from the brain preventing brain damage Who …

A campaign against Alzheimer's disease
12 years, 9 months ago

A campaign against Alzheimer's disease

China Daily  

This is the VOA Special English Health Report. Last week, the United States government announced a major education and research campaign against Alzheimer's disease. By then, experts say Alzheimer's and other dementia disorders could affect as many as 66 million people worldwide. Early next year, scientists at the Banner Alzheimer's Institute in Arizona plan to begin human testing of an …

Discover Related